John B Welsh
Affiliation: Medtronic Inc
- Insights from a large observational database of continuous glucose monitoring adoption, insulin pump usage and glycemic control: the CareLink™ databaseJohn B Welsh
Medtronic, Inc, 18000 Devonshire Street, Northridge, CA 91325, USA
Pediatr Endocrinol Rev 7:413-6. 2010..This study examined CGM usage and its relationship to insulin delivery and glycemia in CareLink users with type 1 diabetes mellitus (T1DM)...
- Usage and effectiveness of the low glucose suspend feature of the Medtronic Paradigm Veo insulin pumpPratik Agrawal
Medtronic, Inc, Northridge, California 91325, USA
J Diabetes Sci Technol 5:1137-41. 2011..The Medtronic Paradigm® Veo™ pump with automatic low glucose suspend (LGS) was released in 2009. Data from 7 months of real-world use of the system were analyzed to assess usage patterns and effectiveness of LGS...
- Practical considerations in the use of real-time continuous glucose monitoring alertsJohn Mastrototaro
Medtronic Diabetes, Northridge, California 91325, USA
J Diabetes Sci Technol 4:733-9. 2010..Real-time CGM is safe and generally well tolerated; however, individualization of alert settings is necessary maximize the system's benefits and patient adherence...
- Designing the modern pump: engineering aspects of continuous subcutaneous insulin infusion softwareJohn B Welsh
Diabetes, Medtronic Inc, 18000 Devonshire Street, Northridge, CA 91325, USA
Diabetes Technol Ther 12:S37-42. 2010..In particular, pumps that are combined with glucose sensors and appropriate algorithms will provide the basis for increasingly safe and precise automated insulin delivery-essential steps to developing a fully closed-loop system...